Welcome to our dedicated page for Caris Life Sciences news (Ticker: CAI), a resource for investors and traders seeking the latest updates and insights on Caris Life Sciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Caris Life Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Caris Life Sciences's position in the market.
Caris Life Sciences (NASDAQ: CAI) will present 19 studies at the San Antonio Breast Cancer Symposium (SABCS) from Dec 9–12, 2025. The research spans seven breast cancer subtypes (HR+/HER2–, HER2+, HER2-low/ultralow/null, triple-negative, invasive lobular, male, metastatic) and reflects multi-omics tumor profiling, whole exome/transcriptome sequencing, IHC, and AI-driven signatures.
Two studies are selected for oral/rapid oral presentation focusing on multimodal AI for recurrence prediction and late distant recurrence risk. The 19 studies involve 40+ collaborating institutions and Caris Precision Oncology Alliance (Caris POA), which includes 98 centers with 45 NCI-designated cancer centers. Abstracts and poster summaries will be available onsite at Caris booth #209 and later on the company website.
Caris Life Sciences (NASDAQ: CAI) announced on Dec 2, 2025 that the UAMS Winthrop P. Rockefeller Cancer Institute joined the Caris Precision Oncology Alliance (Caris POA).
The Caris POA now includes 98 centers, including 45 NCI‑designated cancer centers. Members gain access to Caris' multimodal molecular profiling (genomic, transcriptomic, proteomic) and a large matched clinico‑genomic database containing data from hundreds of thousands of cancer patients with tens of billions of data points per patient to support biomarker‑driven research and trial matching.
Caris Life Sciences (NASDAQ: CAI) announced selection of 15 physician-scientists for the 2025/2026 Caris Precision Oncology Alliance Fellows Forum, a competitive two-year program offering mentorship, hands-on training and access to Caris' CODEai database covering >484,000 patients and over one million data points per patient.
Fellows will receive direct mentorship, collaborative research across 97 cancer institutions, structured education, monthly workshops, lab tours in Phoenix, and participation at the Caris POA Summit at the ASCO Annual Meeting.
Caris Life Sciences (NASDAQ: CAI) will attend multiple investor conferences in Q4 2025 and is offering investor meetings on specific dates. Wolfe Research 7th Annual Healthcare Conference (New York): investor meetings on November 18, 2025. Citi 2025 Global Healthcare Conference (Miami): investor meetings on December 3, 2025. Evercore 8th Annual Healthcare Conference (Miami): investor meetings on December 4, 2025.
Investors and analysts can request meetings by contacting IR@CarisLS.com. Caris is headquartered in Irving, Texas, and describes itself as a patient‑centric AI TechBio company focused on comprehensive molecular profiling and precision medicine solutions.
Caris Life Sciences (Nasdaq: CAI) reported third quarter 2025 results and raised full-year guidance on Nov 5, 2025. Q3 revenue was $216.8M, up 113.4% YoY, driven by molecular profiling services. Management reported net income $24.3M, adjusted EBITDA $51.2M, and gross margin 68.0% (up 2,432 bps). Q3 clinical case volume totaled 50,763 (up 18.2%). Cash provided by operations was $62.4M and free cash flow $55.3M. Company raised 2025 revenue guidance to $720–$730M, implying 75–77% YoY growth.
Caris Life Sciences (NASDAQ: CAI) announced validation of TET2 clonal hematopoiesis (CH) as a biomarker associated with improved response to immune checkpoint inhibitor (ICI) therapy in solid tumors.
The study, led at MD Anderson and published in Cancer Cell, combined laboratory models with analysis of Caris' clinico-genomic database covering ~36,000 NSCLC and >25,000 colorectal cancer patients to show TET2-CH links to enhanced macrophage antigen presentation and better ICI outcomes.
The company highlights potential future use of CH to guide therapy selection while noting these findings inform but do not guarantee changes to clinical practice.
Caris Life Sciences (NASDAQ: CAI) announced it will report third quarter 2025 financial results on Wednesday, November 5, 2025.
The company will host a conference call and live webcast on November 5 at 3:30 p.m. CT (4:30 p.m. ET) to discuss results. Investors can join the live webcast at https://edge.media-server.com/mmc/p/uwjxydsa. A replay will be available shortly after the call on the Investor Relations section of CarisLifeSciences.com.
Caris Life Sciences (NASDAQ: CAI) will present six collaborative studies at the ESMO Congress 2025 in Berlin, Oct 17-21, 2025. The research, from collaborations with 25+ cancer centers and the Caris Precision Oncology Alliance, spans nine tumor types and uses multiomics (WES, WTS, IHC) and real-world clinico-genomic data to inform subtyping, biomarker discovery and treatment decisions.
Formats include one oral proffered paper, one mini-oral and four posters; full abstracts will be posted on the company website after the event.
Caris Life Sciences (NASDAQ: CAI) has published a validation study in Oncotarget for its FDA-approved MI Cancer Seek® companion diagnostic assay. The test is the first and only FDA-approved solution combining whole exome and whole transcriptome sequencing for solid tumor profiling in both adult and pediatric patients.
MI Cancer Seek demonstrates exceptional performance with 97-100% positive and negative agreement compared to other FDA-approved assays. The test analyzes 228 genes for various mutations, microsatellite instability, tumor mutational burden, and copy number amplification in breast cancer patients. Notably, it enables simultaneous RNA and DNA extraction from minimal tissue input, streamlining the testing process and potentially reducing delays in treatment decisions.
Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for HER2-negative breast cancer treatment. The research analyzed over 4,000 patients to evaluate trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG).
Key findings revealed that T-DXd demonstrated superior effectiveness in hormone receptor (HR)-positive patients, while SG showed better results as first-line treatment for HR-negative and HER2-null tumors. For triple-negative breast cancer patients, both treatments showed comparable benefits, emphasizing the importance of personalized treatment approaches.
FAQ
What is the current stock price of Caris Life Sciences (CAI)?
What is the market cap of Caris Life Sciences (CAI)?
